The hidden half of lipid nanoparticle manufacturing: Downstream processing
Journal of Controlled Release · 2026
DOI: 10.1016/j.jconrel.2026.115189 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2026. Verfasst von Peter Sagmeister und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: Nanoparticles, Lipids, Technology, Pharmaceutical. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 126 Literaturangaben. Gefördert von: FDA, US Food and Drug Administration.
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) are the dominant nonviral delivery platform for nucleic acid therapeutics, yet their manufacturing remains complex and difficult to scale reproducibly. Downstream operations, particularly membrane-based unit operations such as buffer exchange and sterile filtration, are central determinants of LNP manufacturability but remain comparatively underrepresented in the academic literature relative to upstream particle formation. This Review demonstrates that downstream processing actively reshapes critical product quality attributes, including particle size, morphology, internal structure, payload distribution, and stability. Each downstream unit operation imposes distinct physicochemical perturbations that collectively determine the final drug product. Many of these changes are formulation-dependent and directly influence biological performance. We identify key knowledge gaps in analytical technologies, mechanistic understanding, and process development practices, and argue that robust LNP manufacturing requires upstream and downstream operations to be designed as a single, coupled process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.
- Lonza Specialized Modalities, Geleen, the Netherlands.
- Process Technology Design, Sterile Technology LLC, Wilmington, DE, USA.
- MB Chemistry Consulting Ltd., UK.
- Department of Chemical Engineering, 404 Chemical & Biomedical Engineering Building, The Pennsylvania State University, University Park, PA 16802, USA.
- Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA. Electronic address: myerson@mit.edu.
Förderung
- FDA
- US Food and Drug Administration
Zitieren
APA
Sagmeister, P., Devos, C., Udepurkar, A., Schwenger, A., Webb, C., McDonald, A., Berry, M., Zydney, A. L., Braatz, R. D., & Myerson, A. S. (2026). The hidden half of lipid nanoparticle manufacturing: Downstream processing. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2026.115189
Vancouver
Sagmeister P, Devos C, Udepurkar A, Schwenger A, Webb C, McDonald A, et al. The hidden half of lipid nanoparticle manufacturing: Downstream processing. Journal of Controlled Release. 2026. doi:10.1016/j.jconrel.2026.115189
BibTeX
@article{Sagmeister2026,
author = {Sagmeister, Peter and Devos, Cedric and Udepurkar, Aniket and Schwenger, Alexander and Webb, Cameron and McDonald, Austin and Berry, Malcolm and Zydney, Andrew L and Braatz, Richard D and Myerson, Allan S},
title = {The hidden half of lipid nanoparticle manufacturing: Downstream processing},
journal = {Journal of Controlled Release},
year = {2026},
doi = {10.1016/j.jconrel.2026.115189}
}
EUVIMED